Drew Tenney joined Neurotech in the fall of 2024 as the Head of US Commercial Operations. He is growth-focused with a passion for building and scaling high-performing commercial organizations from the ground up.
Drew has more than 25 years of industry experience and a proven track record of driving double and triple-digit revenue growth. He began his career with Pfizer as a sales representative. After several years working across roles of increasing responsibilities in sales, marketing and commercial operations, Drew joined Genzyme building the commercial infrastructure for their multiple sclerosis business unit.
Following Sanofi’s acquisition of Genzyme, Drew led the strategic integration of Genzyme’s specialty and rare disease products into Sanofi’s portfolio. In that capacity he oversaw all facets of commercial operations across multiple therapeutic areas. Following his time with Sanofi and Genzyme, Drew led commercial operations at both Ocular Therapeutix and Avadel Inc. In total Drew has launched more than a dozen products across multiple therapeutic areas and took seven of those launches to blockbuster status within eighteen months of launch.
Drew holds a Bachelor of Business Administration in both marketing and business from Loyola University Maryland.
